Skip to main content
. 2021 Oct 8;11:20073. doi: 10.1038/s41598-021-99713-y

Table 4.

Meta-analysis of treatment received between survivor and non-survivor kidney transplantation patients.

Variables Survivors Non-survivors Number of patients reported Number of studies reporting Pooled odds ratio (95% CI) p-value from random effects model I2 index (%) Q-test p-value Egger’s test p-value
Ventilator support or intubation (%) 68 (5.3) 224 (64.0) 1,645 6 56.45 (9.67, 329.62)  < 0.001 93.1  < 0.001 0.007
Withhold CNIs (%) 32 (6.9) 46 (39.3) 582 4 10.07 (0.76, 132.62) 0.08 93.1  < 0.001  < 0.001
Withhold antimetabolites (%) 379 (75.2) 110 (84.6) 634 5 1.66 (0.92, 2.99) 0.09 0 0.39 0.46
Hydroxychloroquine (%) 716 (55.3) 226 (64.6) 1,645 6 1.55 (1.20, 2.00)  < 0.001 0 0.38 0.29
Steroid (%) 550 (42.5) 240 (68.6) 1,645 6 4.40 (1.70, 11.38) 0.002 81.6 0.002 0.014
Antibiotics (%) 553 (44.0) 169 (50.1) 1,593 5 1.91 (1.06, 3.46) 0.031 46.3 0.10 0.013
Antivirals (%) 273 (21.1) 107 (30.6) 1,645 6 1.99 (1.36, 2.93)  < 0.001 15.8 0.17 0.15
Tocilizumab (%) 120 (9.3) 90 (25.7) 1,645 6 5.40 (1.54, 18.88) 0.008 88.1  < 0.001 0.88
Convalescent plasma (%) 8 (2.6) 15 (21.4) 381 3 8.76 (1.85, 41.5) 0.006 56.2 0.10 0.86

CNI; calcineurin inhibitor.